News About: Pharm. Affairs
Only 3 medicines developed in Korea with manufacturing performance more than KRW 50 billion for 5 years
A product which was manufactured the most for 5 years between 2012 and 2016 was reportedly Boryung Pharm’s ‘Kanarb.’
Moreover, there were only 3 products which were manufactured for more than KRW 50 billion in the pe...
Fines imposed on a drug having no substitute for exposure of illegal rebates
If a drug exposed for illegal rebate has no clinical substitute, suspension of health insurance benefit will be replaced to a fine.
If a drug cannot be prescribed, supplied or distributed, has a risk to cause serious...
Lixiana put up a great fight in NOAC market in beginning of 2nd yearly half
The Lixiana’s growth trend has drawn attention in the novel oral anticoagulant(NOAC) market in the beginning of the 2nd yearly half. The product not only showed an increase rate among other products on July compared t...
Trendy ‘targeted therapy’ working on ulcerative colitis treatment too
‘Targeting’ has been a trend in the new drug development market for the past several years. New drugs had been developed with a mechanism of affecting the entire body, but the new drug paradigm is now changing to affe...
Kuhnil Pharm acquires approval of Omega-3/rosuvastatin combination drug for first time in the world
Kuhnil Pharm(CEO Young-Joong Kim) announced approval of Rosumega SC(generic name: omega-3-acids ethyl esters 90 + rosuvastatin) from the Ministry of Food and Drug Safety on the 31st of July.
Rosumega SC will be used ...
4-way competition in NOAC market, well-played by Eliquis and Lixiana
While 4 products are settled in the novel oral anticoagulant(NOAC) market, competition is expected to get fiercer.
Bayer’s Xarelto(rivaroxaban) gained the summit of the market; BMS’s Eliquis(apixaban) and a new stron...
“It needs linkage among consumers, pharmacists and pharmaceutical companies to indicate information for common drugs”
It was suggested the phased information indication and transmission system needs improvements to connect among customers, pharmacists and pharmaceutical companies instead of being a simple product guide.
At the ‘2017...
170 recalls for pharmaceutical products last year, accounting for more than 10% of the total
The number of recalls was the total 1,603 cases last year, and 170 of them were pharmaceutical products.
The Fair Trade Commission analyzed the number of recalls from government bodies, such as Ministry of Land, Infr...
Insurance benefit committee accepted benefits of Olita Tab and Tagrisso Tab on August
Hanmi Pharm’s ‘Olita Tab’ and AstraZeneca Korea’s ‘Tagrisso Tab’ were recognized propriety of the health insurance benefits.
The Health Insurance Review & Assessment Service’s Health Insurance Benefit Evaluation Comm...
Is U.S. drug market impregnable? Korean pharma & bio companies’ accelerated entry to the market
Becoming a global pharmaceutical company has become an topic of conversation among Korean pharmaceutical and biotechnology companies.
A barrier that pharmaceutical and biotechnology companies focusing on R&D consider...
